MKI67 and neoplasm: Treatment plans for neuroendocrine tumors typically begins with the surgical pathology assessment of tumor aggressiveness that is based on assessing mitotic count, intracellular Ki-67 protein levels, and morphologic features of differentiation, including higher mitotic count, higher Ki-67 levels, and poorly differentiated histological morphology being associated with more aggressive tumor and poorer prognosis (Rogoza et al. 2022).